Arena Pharmaceuticals, Inc.

Karin Lehmann-Bruinsma

Chen Wang Liaw

I-Lin Lin

The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is known ('known GPCRs'), and most particularly to mutated (non-endogenous) versions of the known GPCRs for use, most preferably in screening assays for the direct identification of candidate compounds as inverse agonists, agonists and partial agonists.

Non-endogenous, constitutively activated known G protein-coupled receptors

The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is known (&ldquo;known GPCRs&rdquo;), and most particularly to mutated (non-endogenous) versions of the known GPCRs for use, most preferably in screening assays for the direct identification of candidate compounds as inverse agonists, agonists and partial agonists.

Growing community of inventors

San Diego, CA, United States of America

Karin Lehmann-Bruinsma